A New Modification of Temporary Suture-Holding Technique for Transcatheter Repair of Sinus Venosus Atrial Septal Defect.

Pediatr CardiolJan 21, 2026 (epub)
Case ReportCardiologyOpen access

Ihsan A Elhalabi, Ziyad M Hijazi

✦ AI-curated · Sources linked

Case in brief

A 14-year-old boy with a superior sinus venosus atrial septal defect and partial anomalous return of the right middle and upper pulmonary veins underwent transcatheter repair with a covered stent. The team used a modified temporary holding-wire technique: a guidewire placed through the stent’s outermost strut was exteriorized via the internal jugular vein to control stent position. An 80-mm covered stent, anchored proximally with a 28-mm bare-metal stent, completely excluded the atrial communication and redirected anomalous venous flow to the left atrium without obstruction.

What made this case unusual

The modification replaced the temporary suture with an exteriorized guidewire threaded through the stent’s outermost strut, allowing stent control and fluoroscopic visualization during deployment.

Diagnostic / clinical pearl

In transcatheter repair of superior sinus venosus defects, temporary control of the covered stent’s position is a key technical challenge; this case describes a guidewire-based holding method that provided grip and fluoroscopic visibility.

Why it matters

The authors suggest this simple modification may improve procedural control and safety and broaden the applicability of transcatheter repair.

Source

Published in Pediatr Cardiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.